Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN PEDIATRIC versus SULFAMETHOXAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN PEDIATRIC versus SULFAMETHOXAZOLE.
GANTRISIN PEDIATRIC vs SULFAMETHOXAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfisoxazole is a competitive inhibitor of bacterial dihydropteroate synthase, preventing the incorporation of para-aminobenzoic acid (PABA) into dihydrofolate, thereby inhibiting bacterial folic acid synthesis.
Displaces dihydropteroate synthetase from its substrate para-aminobenzoic acid (PABA), inhibiting bacterial folate synthesis. Bacteriostatic against susceptible organisms.
2-4 g initially, then 4-6 g/day in 3-6 divided doses orally, depending on severity. Alternatively, for sulfisoxazole (the active moiety), typical adult dose is 500 mg to 1 g orally every 6 hours. IM use: 50 mg/kg initially, then 100 mg/kg/day in divided doses every 6-8 hours. IV use: Not recommended in pediatric formulation.
800 mg sulfamethoxazole with 160 mg trimethoprim (DS tablet) orally every 12 hours.
None Documented
None Documented
Clinical Note
moderateSulfamethoxazole + Gatifloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfamethoxazole + Rosoxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfamethoxazole + Trovafloxacin
"Sulfamethoxazole may increase the hypoglycemic activities of Trovafloxacin."
Clinical Note
moderateSulfamethoxazole + Nalidixic acid
Terminal elimination half-life is 6-12 hours (prolonged in renal impairment; up to 30 hours in patients with creatinine clearance <10 mL/min).
9-11 hours in adults with normal renal function. Prolonged in renal impairment: up to 20-30 hours. In neonates, 6-12 hours.
Primarily renal (70-100% as unchanged drug and acetylated metabolites) via glomerular filtration and tubular secretion; <10% fecal.
Primarily renal; ~80-90% excreted unchanged in urine, with 15-30% as acetylated metabolite. Biliary/fecal <5%.
Category C
Category D/X
Sulfonamide Antibiotic
Sulfonamide Antibiotic
"Sulfamethoxazole may increase the hypoglycemic activities of Nalidixic acid."